GlaxoSmithKline plc with ticker (LON:GSK) now has a potential downside of -6.8% according to Barclays.
Barclays set a target price of 1,350 GBX for the company, which when compared to the GlaxoSmithKline plc share price of 1,442 GBX at opening today (27/10/2021) indicates a potential downside of -6.8%. Trading has ranged between 1,191 (52 week low) and 1,529 (52 week high) with an average of 7,517,710 shares exchanging hands daily. The market capitalisation at the time of writing is £71,994,195,608.
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
GlaxoSmithKline plc -6.8% potential downside indicated by Barclays
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Anthony Fox
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.
GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic.
GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
